# Novartis Drug Reduces Inflammation; Heart Benefits Still Unproven

Novartis reported that its newly acquired drug pacibekitug lowered signs of inflammation in a clinical study. The key question now is whether that effect will translate into improved heart outcomes for patients.

The drug targets the IL-6 pathway, which is involved in systemic inflammation. In the study, treatment with pacibekitug produced measurable reductions in inflammatory markers. The company has not yet released data on whether these changes lead to fewer heart attacks, strokes, or other cardiovascular events.

The findings were presented as part of the Tourmaline trial program. Novartis acquired the drug as part of a recent deal. The company plans further analysis to determine if the anti-inflammatory effect can reduce cardiovascular risk.

Inflammation is a recognized factor in atherosclerosis and other forms of heart disease. Many existing heart therapies work by lowering cholesterol or blood pressure, but few specifically target inflammatory pathways. A drug that safely lowers inflammation could fill an important gap in preventive cardiology, especially for patients who remain at risk despite standard treatments.

However, showing that a drug reduces a biological marker is not enough to prove clinical benefit. The medical community will wait for hard evidence that pacibekitug improves survival or reduces cardiac events. Novartis has indicated it will continue studying the drug toward that goal.

Source: [original report](https://www.statnews.com/2026/08/29/novartis-pacibekitug-inflammation-il6-tourmaline-heart-disease/?utm_campaign=rss)